

Invited Mini Review

Gut microbiota-generated metabolites: missing puzzles to hosts' health, diseases, and aging

Yan Zhang¹, Shibo Wei², Hang Zhang³, Yunju Jo², Jong-Sun Kang¹, Ki-Tae Ha⁴, Jongkil Joo⁵, Hyun Joo Lee^{5,*}
& Dongryeol Ryu^{2,*}

¹Department of Molecular Cell Biology, Single Cell Network Research Center, Sungkyunkwan University, Suwon 16419, ²Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea, ³Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun 130041, China, ⁴Department of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan 50612, ⁵Department of Obstetrics and Gynecology, Pusan National University Hospital, Busan 49241, Korea

The gut microbiota, an intricate community of bacteria residing in the gastrointestinal system, assumes a pivotal role in various physiological processes. Beyond its function in food breakdown and nutrient absorption, gut microbiota exerts a profound influence on immune and metabolic modulation by producing diverse gut microbiota-generated metabolites (GMGMs). These small molecules hold potential to impact host health via multiple pathways, which exhibit remarkable diversity, and have gained increasing attention in recent studies. Here, we elucidate the intricate implications and significant impacts of four specific metabolites, Urolithin A (UA), equol, Trimethylamine N-oxide (TMAO), and imidazole propionate, in shaping human health. Meanwhile, we also look into the advanced research on GMGMs, which demonstrate promising curative effects and hold great potential for further clinical therapies. Notably, the emergence of positive outcomes from clinical trials involving GMGMs, typified by UA, emphasizes their promising prospects in the pursuit of improved health and longevity. Collectively, the multifaceted impacts of GMGMs present intriguing avenues for future research and therapeutic interventions. [BMB Reports 2024; 57(5): 207-215]

INTRODUCTION

The gut microbiota represents a complex community of bac-

teria inhabiting the human gastrointestinal tract that exert a pivotal influence over a multitude of physiological processes, such as digestion, immune regulation, and metabolic homeostasis (1). The gut microbiota transcends its role as a mere consortium of microorganisms within the body, as it profoundly influences the subject's health by producing various kinds of metabolites, referred to as GMGMs (2). The gut microbiota participates in nutrient metabolism and energy provision by absorbing glucose, amino acids, and lipids. During the utilization of these substrates, various metabolites are produced, such as phenolic compounds from protein and short-chain fatty acids from carbohydrate. These metabolites further exert positive or negative effects on human health (3, 4). GMGMs typically consist of small molecules that can impact the host through multiple pathways. Some of these metabolites can influence the host's metabolic processes, assisting in the maintenance of weight balance and blood glucose stability (5). Conversely, others may impact the immune system function, regulating inflammatory processes within the host (6). Research into the interplay between metabolites and their implications for health, disease, and the aging process is continually advancing. Remarkably, specific metabolites have been discovered to exhibit profound connections with overall health issues (7). For example, certain beneficial bacteria create antioxidants and anti-inflammatory chemicals that lower the risk of chronic diseases (8, 9). Other specific metabolites wield influence over brain health by altering cognitive performance and emotional regulation (10, 11). On the other hand, detrimental disturbances to the gut microbiota have been associated with the pathogenesis of different disorders. Recent investigations have elucidated links between gut microbiota dysbiosis and ailments, such as gastrointestinal inflammation, inflammatory bowel disease, and obesity (12-15). These explorations contribute significantly to our comprehension of the pathogenic mechanisms underlying specific disorders, providing valuable advances in corresponding therapeutic interventions. In this review, we provide an overview of recent investigations on GMGMs and their intricate interconnections with human health and disease. Furthermore,

*Corresponding authors. Dongryeol Ryu, Tel: +82-62-715-5374; Fax: +82-62-715-5309; E-mail: dryu@gist.ac.kr; Hyun Joo Lee, Tel: +82-51-240-7288; Fax: +82-51-248-2384; E-mail: atouchof@pusan.ac.kr

<https://doi.org/10.5483/BMBRep.2024-0022>

Received 17 October 2023, Revised 7 March 2024,
Accepted 20 March 2024, Published online 9 April 2024

Keywords: Aging, Gut microbiome, Gut microbiota-generated metabolites, Mitophagy, Urolithin A

we have deliberated on the advanced techniques and clinical trials involving GMGMs, which may provide prospective insights for future research and therapeutic strategies.

GMGMs

GMGMs are highly diverse, and research in this domain remains in a perpetual state of evolution. In this section, we elucidate four metabolites currently under intensive investigation. Two of those, UA and equol, have been substantiated for their beneficial effects upon the human body, whereas the other two, TMAO and imidazole propionate, are generally recognized to have detrimental impacts (Fig. 1).

UA, A FIRST-IN-CLASS MITOPHAGY ENHANCER

UA is a natural compound originally derived from the microbial metabolism of diets rich in ellagitannins, with its primary

component, ellagic acid, undergoing a series of metabolic transformations into UA (Fig. 2A) (16, 17). Extensive research efforts spanning several decades have been dedicated to UA, with its potential health benefits attracting substantial scientific attention and continued exploration as research advances. Notably, UA has demonstrated the capacity to ameliorate diverse health conditions, with a particular emphasis on its role in promoting mitophagy, which has emerged as a focal point in the realm of disease recovery (18, 19). Mechanically, by stabilizing PTEN-induced kinase 1 (PINK1), and recruiting PARKIN, also known as PRKN/PARK2, UA triggers the recognition and labeling of damaged mitochondria. PINK1 accumulates on damaged mitochondria and activates PARKIN, leading to the ubiquitination of mitochondrial proteins and the recruitment of LC3. In a coordinated manner, UA also independently activates BNIP3/LC3 pathway, facilitating phagophore membrane formation and ultimate elimination via the cellular process of mitophagy, thereby preserving the health and functionality of mito-




Fig. 1. The impacts of gut microbiota-derived metabolites (GMGM) in diverse tissues. GMGM, of both beneficial (urolithin A [UA] and equol) and detrimental (Trimethylamine N-oxide and imidazole propionate) influence, exhibit a diverse range of effects on various tissues, playing crucial roles in the regulation of human health. PCOS, polycystic ovary syndrome.




Fig. 2. The mitophagy activator UA demonstrates evident therapeutic benefits and efficacy in experimental models and humans. (A) After the consumption of diets rich in ellagitannins (such as pomegranate, berries, and nuts), the primary component, ellagic acid, is metabolized and converted to UA by the gut microbiota. (B) UA activates mitophagy via PINK1/PARKIN and BNIP3/LC3 pathways, respectively. UA stabilizes PINK1 kinase, then phosphorylating Ubiquitin while recruiting PARKIN. PARKIN subsequently ubiquitinates mitochondrial proteins, which facilitates ubiquitin chains formulation and interaction with mitophagy adaptor proteins (such as p62) to bind with LC3. Additionally, UA activates the BNIP3 protein, resulting in the recruitment of LC3 and the formulation of phagophore membrane. Ultimately, via the concerted fusion of lysosomes, dysfunctional mitochondria form mitophagosomes, leading to their eventual degradation. PINK1, PTEN-induced kinase 1; OMM, outer mitochondrial membrane. (C) UA has demonstrated multiple therapeutic benefits in experimental models (*C. elegans* and rodents) and clinical trials (middle-aged adults and elders), indicating its promising potential for future research and therapeutic interventions. PK/PD, pharmacokinetic/pharmacodynamic.

chondria (Fig. 2B) (17).

As a first-in-class mitophagy enhancer, UA improves mitochondrial quality control by assisting in the clearance of damaged or aging mitochondria, contributing to the mitigation of various pathological processes in a wide range of species, spanning from *C. elegans* and rodents to humans (Fig. 2C). UA has been proven to extend lifespan and enhance healthy aging in *C. elegans*, with notable improvements of respiratory capacity, mobility, and pharyngeal pumping (16). In view of these findings, researchers have extended investigations into mammals to clarify the therapeutic effects of UA on muscle-related aspects. Muscle health is crucial for preserving mobility, particularly with aging. During the aging process, a decline in mito-

phagy in muscles can be considered a contributing factor to muscle weakness (20). UA has been demonstrated to effectively improve physical performance, characterized by muscle strength and exercise endurance in young and aged mice (16). Notably, UA supplementation can improve mitochondrial metabolic efficiency, lower levels of inflammation-related biomarkers in the blood, and significantly improve muscle endurance in human. This is critical for preventing age-related muscular weakening and functional decline, highlighting the profound prospects and applications of UA in improving human health (21-23). In addition to its remarkable muscular benefits, recent studies also identified UA as a highly promising therapeutic candidate for the maintenance of cardiovascular health,

as it effectively reduces age-related heart failure, as well as reserving cardiac function (24). Mitochondrial dysfunction in aging hearts is a contributing factor to the decline of heart function, which is closely associated with the downregulation of mitophagy and reduced clearance rates in aging hearts (25). UA administration significantly counteracted mitochondrial and cardiac dysfunction, as evidenced by the improvements in cardiac contractility and calcium dynamics (26, 27). In addition, UA has also demonstrated curative effects in tumor immunotherapy. T-Stem cell memory (TSCM) cells play a key role in preventing T cell exhaustion and promoting anti-tumor T-cell responses (28). UA activates tumor immune response by inducing the formation of TSCM cells, and its involvement in this process is intricately linked to mitophagy, which enhances T-cell function and the effectiveness of immunotherapy (29). Likewise, UA exhibits considerable benefits in addressing neurological disorders, primarily owing to its remarkable antioxidant properties and its potential to mitigate neuroinflammation, thus exerting neuroprotective effects (30, 31). Specifically, UA provided neuroprotection in Parkinson's disease (PD) by triggering mitophagy in microglial cells, thereby restoring mitochondrial function and reducing the activation of NLRP3 inflammasomes, which, in turn, alleviates the inflammatory response and neurological symptoms (32). In this regard, UA has emerged as a valuable strategy for ameliorating neurodegeneration and inflammation driven by microglial cells. Consistently, UA is implicated in regulating reactive neurogliosis and inflammation signaling pathways, and proving to be protective against the pathology of Alzheimer's disease (AD) (33). Additional study has shown the mitophagy induction of UA in auditory cells as well, thereby preventing age-related hearing loss (34). Beyond its induction in mitophagy, UA has demonstrated therapeutic efficacy in preventing oocyte aging (35), as well as inhibiting endometrial cancer proliferation via the regulation of estrogen receptor- α dependent gene expression (36). Collectively, decades of research have unveiled that UA holds significant potential in the treatment of multiple diseases, especially age-related disorders. Meanwhile, the investigation of UA at the molecular levels has remained comparatively limited, underscoring the necessity for more comprehensive and in-depth studies in this area.

EQUOL, A GUT MICROBIOTA-GENERATED ISOFLAVONOID

Equol is produced by specific bacterial biotypes in the human and animal guts through the metabolism of soy isoflavones. It exists in two diastereoisomeric forms, S-equol and R-equol, with S-equol having received more attention (37). Equol is thought to provide potential health benefits, but not everyone can generate equol after diet consumption. Only 20-30% of individuals in Western populations produce S-equol, whereas among Asians, the percentage rises to approximately 50-70% (38). Due to its structural similarity to estrogen, a significant

portion of research focuses on its binding to estrogen receptors, and its effects in cells and tissues. This resemblance has raised concerns regarding its potential association with breast cancer risk (39). It is reported that appropriate equol supplementation may serve as an effective alternative to hormone therapy in controlling appetite, obesity and metabolic syndrome, as well as alleviating symptoms of perimenopause (40). Furthermore, in the context of male prostate-related diseases, equol may contribute to the prevention of prostate cancer and benign prostatic hyperplasia (41).

The protective effects of equol on heart and brain are gradually gaining recognition. Recent study has indicated its neuro-protective properties in PD (42). S-equol has shown potential benefits in treating atherosclerosis and may have the potential to prevent dementia and coronary heart disease (43, 44). Meanwhile, S-equol supplementation has been shown to ameliorate emotion dysregulation in females with premenstrual symptoms (45), which might be contributed by its estrogenic actions in the brain (46). In line with this, its antidepressant effect has also been observed in obese individuals, implying its curative promise in 'metabolic-mood syndrome' (47). In addition, S-equol displays protective potential in addressing cognitive decline and dementia, suggesting that S-equol may effectively penetrate the blood-brain barrier, allowing its excellent antioxidant and anti-inflammatory effects to be exerted within the brain (48). Meanwhile, its antioxidant properties are also clarified in relation to skin, with the potential of reducing skin aging (39). Evidence of equol's effects on female health presents a nuanced panorama. A cross-sectional investigation reveals a positive correlation between equol levels and the risk of female uterine leiomyomata (49), in accord with observations implicating equol in the induction of uterine tissue hyperplasia (50). Equol has also exhibited the capacity to impede growth and induce atresia in cultured murine ovarian follicles (51). Nevertheless, an interventional study involving isoflavone supplementation among female polycystic ovary syndrome (PCOS) patients yielded intriguing outcomes, with enhancements noted in microbial alpha diversity and glucose homeostasis. Additionally, heightened equol production exhibited an association with favorable fertility markers (52). As such, it is worth noting that as research continues to validate the curative effects of equol, its specificity ought to be taken into consideration. There are significant individual differences, and when considering its effects, the influence of genetics and diet, as well as other factors, should not be overlooked.

TMAO, AN AMINE OXIDE AND OSMOLYTE

TMAO is an organic osmolyte methylamine compound synthesized in human and various animals through a series of metabolic processes. After consuming a diet rich in choline compounds, the gut microbiota catalyzes these substances into trimethylamine (TMA) through a series of biochemical reactions. TMA is subsequently absorbed into the bloodstream via

the intestinal mucosa and undergoes conversion into TMAO in the liver (53, 54). TMAO can protect proteins inside deep-sea organisms from being damaged by high pressure, enabling them to adapt to the high osmotic pressure environment (55). Correspondingly, accumulating investigations have progressively revealed the adverse implications of TMAO in specific aging disorders. Elevated TMAO levels promote the formation of foam cells, impair normal endothelial function, and render atherosclerotic plaques more prone to rupture (56). In AD, TMAO leads to the accumulation of amyloid- β peptides and tau proteins, activates astrocytes, and promotes inflammatory responses (57, 58). Additionally, abnormal TMAO levels are further associated with insulin resistance, and contribute to metabolic dysfunction, which holds substantial significance in the context of both diabetes and obesity (59, 60). Increased levels of circulating TMAO in plasma have also been linked to the etiology of PCOS without hyperandrogenism, exhibiting a concomitant correlation with heightened systemic inflammation, while elevated TMAO could further lead to an exacerbation of cardiovascular risk factors in patients with PCOS (61, 62). As such, TMAO is generally regarded as a detrimental metabolite, while recent studies have revealed intriguing contradictions whereby patients with higher plasma TMAO levels achieve enhanced immunotherapy efficacy by evoking endoplasmic reticulum and enhancing antitumor immunity (63). This paradox underscores the intricate crosstalk between metabolite and immunity, while also highlighting the gaps in our current comprehension of TMAO and possibly other metabolites as well, indicating the necessity for further mechanistic studies and research endeavors.

IMIDAZOLE PROPIONATE, A HISTIDINE METABOLITE

Imidazole propionate is a metabolite that was initially found to be elevated in individuals with diabetes. It was subsequently identified as a microbially produced histidine-derived metabolite, and its inhibitory role in insulin signaling has been revealed (64). Accumulating evidence has gradually unmasked the link between imidazole propionate levels and diet, gut microbiota composition, and obesity. The levels of imidazole propionate are typically elevated in obese individuals, and lower in those with normal weight (65, 66). Due to its impact on glucose metabolism and insulin sensitivity, the influence of imidazole propionate in diabetes has been corroborated in several studies. It has the potential to influence the efficacy of diabetes medications, such as metformin, as well as being correlated with diabetic complications (67-69). Recent research has also confirmed an association between the levels of imidazole propionate and heart failure, with imidazole propionate serving as a predictive marker for overall survival following heart failure (70-72). Despite these insights, the specific mechanisms of imidazole propionate in diseases and its associations with different health conditions have not yet been fully understood.

ADVANCED RESEARCH ON GMGMs

In clinical treatments, the discovery of new candidates and demonstrating their efficacy are of paramount importance. However, in addition to the inherent effectiveness of the drug, the efficient delivery of candidates and the precise control of their release to align with the desired outcomes pose significant and formidable challenges. In current research, various technologies for supplementary drugs delivery and release have emerged. For instance, nanoparticles are widely utilized in the development of drug delivery systems. By encapsulating drug carriers within nanoscale particles, it is possible to enhance the solubility, stability, and targeting of drugs (73, 74). Researchers have converted UA into biodegradable nanoparticles for oral administration in the treatment of acute kidney injury in mice, thereby enhancing the oral bioavailability of UA, and ultimately improving the survival rate of mice (75). Additionally, the application of hydrogels has also contributed to this direction, evidenced by the locally delivered NECA, an agonist of adenosine, with hydrogel implant enhancing neovascularization in islet transplantation (76). These existing studies make clear that the advanced biomaterials and delivery technologies possess multifaced benefits, pointing to their extensive potential applications in the realm of GMGMs, with the UA example being a good illustration. With more flexible control over drug targeting, the beneficial or harmful effects of metabolites may be reevaluated. For instance, as previously mentioned, TMAO has consistently emerged as a risk factor in human, while it also promotes antitumor immunity in breast cancer (63). In this case, exploring novel techniques that enhance the safety and targeting of TMAO via advanced biomaterials may represent a promising avenue for breast cancer therapy. Similarly, the application of other metabolites can also be considered to maximize their benefits, while minimizing potential risks. Such approaches may hold potential for optimizing the therapeutic effects of specific metabolites and ensuring their safety.

GMGMs IN CLINICAL STUDIES

The studies of GMGMs are growing more in-depth, and their performance in clinical trials is receiving widespread attention. In a randomized clinical trial conducted with elderly participants, individuals who are supplemented with UA show evident improvements in muscle endurance, as well as mitochondrial health, compared to the placebo group (21). In another clinical trial involving middle-aged adults, researchers found that UA could enhance muscle strength, and have a positive impact on aerobic endurance and physical performance (22). Furthermore, Nestlé Health Science is currently conducting two randomized, double-blind, placebo-controlled Phase II clinical trials aimed at quantifying the effects of UA on muscle health and function, as well as evaluating its impact on other parameters. Apart from UA, a 24-week randomized, double-blind, placebo-controlled clinical trial on Equol is investigating its

effects on 24-hour dynamic blood pressure, vascular function, and other cardiovascular risk factors, including lipid profiles, glucose metabolism control, and inflammatory markers, in 207 postmenopausal women who do not produce Equol (77). However, there appears to be limited reporting on clinical trials targeting TMAO and imidazole propionate. While latest clinical investigations have revealed that high level of TMAO is considered a risk factor for multiple aging-related diseases (78). For instance, a latest case-control clinical study revealed that TMAO, as well as its nutrient precursor choline, independently correlated with the incident risk for CVDs development (79). TMAO concentration was also reported to be closely correlated with age and positively associated with higher systolic blood pressure and arterial stiffness (80). Additionally, elevated TMAO expression was linked to the incidence of diverse metabolic syndrome, such as type 2 diabetes, obesity, and dyslipidemia (81). Notably, several observational and prospective clinical studies have highlighted TMAO as a potentially predictive biomarker indicating the diagnosis of CVDs and metabolic syndromes (82, 83), as well as the prognosis of conditions including acute coronary syndrome, myocardial infarction, chronic kidney disease, and AD (84-86). Moreover, in studies related to HIV infection, imidazole propionate has been found to be associated with carotid atherosclerosis (87). The latest study further links circulating imidazole propionate plasma levels to coronary artery disease in people with HIV (88). GMGMs are garnering growing attention in the realms of health and disease, prompting expectations for a surge in related research and clinical trials in the future. Advances in the field of research could lead to further studies to delve into their biological functions and potential medical applications.

PERSPECTIVES

Due to the increasing severity of global population aging, there is a growing investment in the prevention and treatment of chronic diseases, with a desire for safer and long-term use medications. In this context, research on GMGMs holds significant benefits and huge potential. With technological advances, more metabolites are being identified, and their importance in various diseases is becoming increasingly evident, including gastrointestinal disorders, CVDs, obesity, diabetes, and cancer (89-92). GMGMs exert their effects through multiple mechanisms, including the regulation of cellular metabolism, modulation of the immune system, and influence on mitochondrial function, among others. While more research is needed to fully understand their specific mechanisms in the human body and the molecular pathways involved, it is worth recognizing that their complex and diverse effects encompass multi-level and multi-stage regulation in both healthy and diseased states. Moreover, while conducting the related research, it is essential to consider the following issues: First, their involvement in biological activities is diverse, and the relationships among them, as well as with the gut microbiota that mediates their

production, are highly intricate. Current research usually focuses on the role of individual metabolites in specific diseases. However, exploring their interactions, and whether there are competitive or synergistic effects, should be another research focus. Furthermore, substantial individual variations exist in the levels of metabolites within the human body, and in the ways in which these metabolites impact the body. These differences arise not only from diet and geographical factors, but also need to consider genetic factors, as previously noted with Equol. Even when people consume the same foods, they can produce completely different metabolites. When considering the development of these metabolites as pharmaceuticals or dietary intervention strategies for humans, this factor needs to be considered, or else it may be challenging to guarantee the effectiveness. In summary, our understanding of GMGM has been evolving for several decades, but many of the mechanisms involved require further in-depth research. Additionally, there may well be new metabolites identified in the future, and gaining a deeper comprehension of their biological properties can provide new clues for disease prevention and therapeutic strategies.

ACKNOWLEDGEMENTS

The present study was supported by a grant from the Biomedical Research Institute Grant (202302240001), Pusan National University Hospital.

AUTHOR CONTRIBUTIONS

H.J.L and D.R. conceived the study. Y.Z. and S.W. contributed to the primary writing and organization of the manuscript. Y.Z., S.W., and H.Z. conducted the literature review. Y.J., J.S.K., K.T.H., J.J., H.J.L., and D.R. provided overall supervision and revision on the final manuscript. All authors have read and approved the final version of the manuscript.

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Zmora N, Suez J and Elinav E (2019) You are what you eat: diet, health and the gut microbiota. *Nat Rev Gastroenterol Hepatol* 16, 35-56
2. Yang JY and Kweon MN (2016) The gut microbiota: a key regulator of metabolic diseases. *BMB Rep* 49, 536-541
3. Ramakrishna BS (2013) Role of the gut microbiota in human nutrition and metabolism. *J Gastroenterol Hepatol* 28 Suppl 4, 9-17
4. Wang L, Wang S, Zhang Q, He C, Fu C and Wei Q (2022) The role of the gut microbiota in health and cardiovascular diseases. *Mol Biomed* 3, 30
5. De Vadder F, Kovatcheva-Datchary P, Goncalves D et al

- (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell* 156, 84-96
6. Zarour HM (2022) Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. *Cell Metab* 34, 1903-1905
 7. Jeong K, Nguyen V and Kim J (2012) Human milk oligosaccharides: the novel modulator of intestinal microbiota. *BMB Rep* 45, 433-441
 8. Zhai S, Qin S, Li L, Zhu L, Zou Z and Wang L (2019) Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice. *FEMS Microbiol Lett* 366, fnz153
 9. Clifford MN, King LJ, Kerimi A, Pereira-Caro MG and Williamson G (2022) Metabolism of phenolics in coffee and plant-based foods by canonical pathways: an assessment of the role of fatty acid beta-oxidation to generate biologically-active and -inactive intermediates. *Crit Rev Food Sci Nutr* 64, 3326-3383
 10. Cryan JF, O'Riordan KJ, Cowan CSM et al (2019) The microbiota-gut-brain axis. *Physiol Rev* 99, 1877-2013
 11. Rutsch A, Kantsjo JB and Ronchi F (2020) The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. *Front Immunol* 11, 604179
 12. Lavelle A and Sokol H (2020) Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 17, 223-237
 13. Franzosa EA, Sirota-Madi A, Avila-Pacheco J et al (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol* 4, 293-305
 14. Dong LN, Wang M, Guo J and Wang JP (2019) Role of intestinal microbiota and metabolites in inflammatory bowel disease. *Chin Med J (Engl)* 132, 1610-1614
 15. Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JJ, Milagro FI and Martinez JA (2019) Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. *Adv Nutr* 10, S17-S30
 16. Ryu D, Mouchiroud L, Andreux PA et al (2016) Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat Med* 22, 879-888
 17. D'Amico D, Andreux PA, Valdes P, Singh A, Rinsch C and Auwerx J (2021) Impact of the natural compound Urolithin A on health, disease, and aging. *Trends Mol Med* 27, 687-699
 18. Um JH and Yun J (2017) Emerging role of mitophagy in human diseases and physiology. *BMB Rep* 50, 299-307
 19. Park W, Wei S, Kim BS et al (2023) Diversity and complexity of cell death: a historical review. *Exp Mol Med* 55, 1573-1594
 20. Drummond MJ, Addison O, Brunner L et al (2014) Down-regulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women: a cross-sectional comparison. *J Gerontol A Biol Sci Med Sci* 69, 1040-1048
 21. Liu S, D'Amico D, Shankland E et al (2022) Effect of Urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. *JAMA Netw Open* 5, e2144279
 22. Singh A, D'Amico D, Andreux PA et al (2022) Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. *Cell Rep Med* 3, 100633
 23. Dao T, Green AE, Kim YA et al (2020) Sarcopenia and muscle aging: a brief overview. *Endocrinol Metab (Seoul)* 35, 716-732
 24. Andreux PA, Blanco-Bose W, Ryu D et al (2019) The mitophagy activator Urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat Metab* 1, 595-603
 25. Nguyen TT, Wei S, Nguyen TH et al (2023) Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. *Exp Mol Med* 55, 1595-1619
 26. Oh CM, Ryu D, Cho S and Jang Y (2020) Mitochondrial quality control in the heart: new drug targets for cardiovascular disease. *Korean Circ J* 50, 395-405
 27. Savi M, Bocchi L, Mena P et al (2017) In vivo administration of Urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. *Cardiovasc Diabetol* 16, 80
 28. Gattinoni L, Speiser DE, Lichterfeld M and Bonini C (2017) T memory stem cells in health and disease. *Nat Med* 23, 18-27
 29. Denk D, Petrocelli V, Conche C et al (2022) Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. *Immunity* 55, 2059-2073 e2058
 30. Casedas G, Les F, Choya-Foces C, Hugo M and Lopez V (2020) The metabolite Urolithin-A ameliorates oxidative stress in neuro-2a cells, becoming a potential neuroprotective agent. *Antioxidants (Basel)* 9, 177
 31. Wu Y, Yuan Q, Ma Y et al (2023) Dietary intervention with the gut microbial metabolite Urolithin A attenuates lipopolysaccharide-induced neuroinflammation and cognitive deficits via the sirt1/acetyl-NF-kappaB signaling pathway. *Mol Nutr Food Res* 67, e2200401
 32. Qiu J, Chen Y, Zhuo J et al (2022) Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease model. *Neuropharmacology* 207, 108963
 33. Gong Z, Huang J, Xu B et al (2019) Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice. *J Neuroinflammation* 16, 62
 34. Cho SI, Jo ER and Song H (2022) Urolithin A attenuates auditory cell senescence by activating mitophagy. *Sci Rep* 12, 7704
 35. Fonseca E, Marques CC, Pimenta J et al (2021) Anti-aging effect of Urolithin-A on bovine oocytes in vitro. *Animals (Basel)* 11, 2048
 36. Zhang W, Chen JH, Aguilera-Barrantes I et al (2016) Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-alpha-dependent gene expression. *Mol Nutr Food Res* 60, 2387-2395
 37. Setchell KD and Clerici C (2010) Equol: pharmacokinetics and biological actions. *J Nutr* 140, S1363-S1368
 38. Sekikawa A, Ihara M, Lopez O et al (2019) Effect of S-equol and soy isoflavones on heart and brain. *Curr Cardiol Rev* 15, 114-135
 39. Lephart ED (2016) Skin aging and oxidative stress: equol's anti-aging effects via biochemical and molecular mecha-

- nisms. *Ageing Res Rev* 31, 36-54
40. Nishimura Y, Mabuchi K, Takano A et al (2017) S-equol exerts estradiol-like anorectic action with minimal stimulation of estrogen receptor- α in ovariectomized rats. *Front Endocrinol (Lausanne)* 8, 281
 41. Lu Z, Zhou R, Kong Y et al (2016) S-equol, a secondary metabolite of natural anticancer isoflavone daidzein, inhibits prostate cancer growth in vitro and in vivo, through activating the Akt/FOXO3a pathway. *Curr Cancer Drug Targets* 16, 455-465
 42. Johnson SL, Park HY, Vatter DA, Grammas P, Ma H and Seeram NP (2020) Equol, a blood-brain barrier permeable gut microbial metabolite of dietary isoflavone daidzein, exhibits neuroprotective effects against neurotoxins induced toxicity in human neuroblastoma SH-SY5Y cells and *Caenorhabditis elegans*. *Plant Foods Hum Nutr* 75, 512-517
 43. Zuo LS, Tang XY, Xiong F et al (2021) Isoflavone biomarkers are inversely associated with atherosclerosis progression in adults: a prospective study. *Am J Clin Nutr* 114, 203-213
 44. Chuang HL, Chiu CC, Lo C et al (2022) Circulating gut microbiota-related metabolites influence endothelium plaque lesion formation in ApoE knockout rats. *PLoS One* 17, e0264934
 45. Takeda T and Chiba Y (2022) Evaluation of a natural S-equol supplement in treating premenstrual symptoms and the effect of the gut microbiota: an open-label pilot study. *Neuropsychopharmacol Rep* 42, 127-134
 46. Blake C, Fabick KM, Setchell KD, Lund TD and Lephart ED (2011) Neuromodulation by soy diets or equol: antidepressive & anti-obesity-like influences, age- & hormone-dependent effects. *BMC Neurosci* 12, 28
 47. Bax EN, Cochran KE, Mao J, Wiedmeyer CE and Rosenfeld CS (2019) Opposing effects of S-equol supplementation on metabolic and behavioral parameters in mice fed a high-fat diet. *Nutr Res* 64, 39-48
 48. Johnson SL, Kirk RD, DaSilva NA, Ma H, Seeram NP and Bertin MJ (2019) Polyphenol microbial metabolites exhibit gut and blood-brain barrier permeability and protect murine microglia against LPS-induced inflammation. *Metabolites* 9, 78
 49. Yang F and Chen Y (2023) Urinary phytoestrogens and the risk of uterine leiomyomata in US women. *BMC Womens Health* 23, 261
 50. Brown NM, Lindley SL, Witte DP and Setchell KD (2011) Impact of perinatal exposure to equol enantiomers on reproductive development in rodents. *Reprod Toxicol* 32, 33-42
 51. Mahalingam S, Gao L, Gonnering M, Helferich W and Flaws JA (2016) Equol inhibits growth, induces atresia, and inhibits steroidogenesis of mouse antral follicles in vitro. *Toxicol Appl Pharmacol* 295, 47-55
 52. Haudum C, Lindheim L, Ascani A et al (2020) Impact of short-term isoflavone intervention in polycystic ovary syndrome (PCOS) patients on microbiota composition and metagenomics. *Nutrients* 12, 1622
 53. Li X, Hong J, Wang Y, Pei M, Wang L and Gong Z (2021) Trimethylamine-N-oxide pathway: a potential target for the treatment of MAFLD. *Front Mol Biosci* 8, 733507
 54. Janeiro MH, Ramirez MJ, Milagro FI, Martinez JA and Solas M (2018) Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. *Nutrients* 10, 1398
 55. Treberg JR and Driedzic WR (2002) Elevated levels of trimethylamine oxide in deep-sea fish: evidence for synthesis and intertissue physiological importance. *J Exp Zool* 293, 39-45
 56. Geng J, Yang C, Wang B et al (2018) Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. *Biomed Pharmacother* 97, 941-947
 57. Arrona Cardoza P, Spillane MB and Morales Marroquin E (2022) Alzheimer's disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role? *Nutr Rev* 80, 271-281
 58. Buawangpong N, Pinyopornpanish K, Siri-Angkul N, Chattipakorn N and Chattipakorn SC (2022) The role of trimethylamine-N-oxide in the development of Alzheimer's disease. *J Cell Physiol* 237, 1661-1685
 59. Schugar RC, Shih DM, Warrier M et al (2017) The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. *Cell Rep* 19, 2451-2461
 60. Chen S, Henderson A, Petriello MC et al (2019) Trimethylamine N-oxide binds and activates perox to promote metabolic dysfunction. *Cell Metab* 30, 1141-1151 e1145
 61. Annunziata G, Ciampaglia R, Capo X et al (2021) Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide (TMAO) be a major player? A potential upgrade forward in the DOGMA theory. *Biomed Pharmacother* 143, 112171
 62. Eyupoglu ND, Caliskan Guzelce E, Acikgoz A et al (2019) Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 91, 810-815
 63. Wang H, Rong X, Zhao G et al (2022) The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. *Cell Metab* 34, 581-594 e588
 64. Koh A, Molinaro A, Stahlman M et al (2018) Microbially produced imidazole propionate impairs insulin signaling through mTORC1. *Cell* 175, 947-961 e917
 65. van Son J, Serlie MJ, Stahlman M, Backhed F, Nieuwdorp M and Aron-Wisniewsky J (2021) Plasma imidazole propionate is positively correlated with blood pressure in overweight and obese humans. *Nutrients* 13, 2706
 66. Lin K, Zhu L and Yang L (2022) Gut and obesity/metabolic disease: focus on microbiota metabolites. *MedComm* 3, e171
 67. Wu B, Tan L, Wang W, Feng X and Yan D (2022) Imidazole propionate is increased in diabetes and associated with stool consistency. *Diabetes Metab Syndr Obes* 15, 1715-1724
 68. Koh A, Manneras-Holm L, Yunn NO et al (2020) Microbial imidazole propionate affects responses to metformin through p38gamma-dependent inhibitory AMPK phosphorylation. *Cell Metab* 32, 643-653 e644
 69. Molinaro A, Bel Lassen P, Henricsson M et al (2020) Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. *Nat Commun* 11, 5881

70. Molinaro A, Nemet I, Bel Lassen P et al (2023) Microbially produced imidazole propionate is associated with heart failure and mortality. *JACC Heart Fail* 11, 810-821
71. Hua S, Lv B, Qiu Z et al (2023) Microbial metabolites in chronic heart failure and its common comorbidities. *EMBO Mol Med* 15, e16928
72. Raju SC, Molinaro A, Awoyemi A et al (2024) Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity. *Genome Med* 16, 27
73. Kim BR, Yoon JW, Choi H, Kim D, Kang S and Kim JH (2022) Application of periostin peptide-decorated self-assembled protein cage nanoparticles for therapeutic angiogenesis. *BMB Rep* 55, 175-180
74. Ye M, Zhao Y, Wang Y et al (2022) NAD(H)-loaded nanoparticles for efficient sepsis therapy via modulating immune and vascular homeostasis. *Nat Nanotechnol* 17, 880-890
75. Zou D, Ganugula R, Arora M, Nabity MB, Sheikh-Hamad D and Kumar M (2019) Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI. *Am J Physiol Renal Physiol* 317, F1255-F1264
76. Nguyen TT, Emami F, Yook S et al (2020) Local release of NECA (5'-(N-ethylcarboxamido)adenosine) from implantable polymeric sheets for enhanced islet revascularization in extrahepatic transplantation site. *J Control Release* 321, 509-518
77. Liu ZM, Ho SC, Chen YM, Xie YJ, Huang ZG and Ling WH (2016) Research protocol: effect of natural S-sequol on blood pressure and vascular function—a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension. *BMC Complement Altern Med* 16, 89
78. Constantino-Jonapa LA, Espinoza-Palacios Y, Escalona-Montano AR et al (2023) Contribution of trimethylamine N-oxide (TMAO) to chronic inflammatory and degenerative diseases. *Biomedicines* 11, 431
79. Tang WHW, Li XS, Wu Y et al (2021) Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. *Am Heart J* 236, 80-86
80. Brunt VE, Casso AG, Gioscia-Ryan RA et al (2021) Gut microbiome-derived metabolite trimethylamine N-oxide induces aortic stiffening and increases systolic blood pressure with aging in mice and humans. *Hypertension* 78, 499-511
81. Xiong X, Zhou J, Fu Q et al (2022) The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy. *Lipids Health Dis* 21, 60
82. Barrea L, Annunziata G, Muscogiuri G et al (2018) Trimethylamine-N-oxide (TMAO) as novel potential biomarker of early predictors of metabolic syndrome. *Nutrients* 10, 1971
83. Lemaitre RN, Jensen PN, Wang Z et al (2021) Association of trimethylamine N-oxide and related metabolites in plasma and incident type 2 diabetes: the cardiovascular health study. *JAMA Netw Open* 4, e2122844
84. Gao J, Yan KT, Wang JX et al (2020) Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events. *Sci Rep* 10, 2639
85. Zhou X, Jin M, Liu L, Yu Z, Lu X and Zhang H (2020) Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. *ESC Heart Fail* 7, 188-193
86. Tang WH, Wang Z, Kennedy DJ et al (2015) Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. *Circ Res* 116, 448-455
87. Wang Z, Peters BA, Bryant M et al (2023) Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. *Microbiome* 11, 119
88. Troseid M, Molinaro A, Gelpi M et al (2024) Gut Microbiota alterations and circulating imidazole propionate levels are associated with obstructive coronary artery disease in people with HIV. *J Infect Dis* 229, 898-907
89. Jeong SM, Jin EJ, Wei S et al (2023) The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model. *BMB Rep* 56, 404-409
90. Park SJ, Kim JH, Song MY, Sung YC, Lee SW and Park Y (2017) PD-1 deficiency protects experimental colitis via alteration of gut microbiota. *BMB Rep* 50, 578-583
91. Park H, Park NY and Koh A (2023) Scarring the early-life microbiome: its potential life-long effects on human health and diseases. *BMB Rep* 56, 469-481
92. Lo Sasso G, Ryu D, Mouchiroud L et al (2014) Loss of Sirt1 function improves intestinal anti-bacterial defense and protects from colitis-induced colorectal cancer. *PLoS One* 9, e102495